Do Not Coadminister
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Emtricitabine/tenofovir-DF should not be administered with additional tenofovir-DF. Coadministration of tenofovir-DF (300 mg once daily) and emtricitabine (200 mg once daily for 7 days) had no effect on tenofovir AUC, Cmax or Cmin; emtricitabine AUC and Cmax were unaltered and there was a 20% increase in Cmin (n=17).
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing tenofovir disoproxil.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
No clinically significant drug interactions have been observed between FTC and tenofovir. Coadministration of tenofovir-DF (300 mg once daily) and emtricitabine (200 mg once daily) was studied in 17 subjects. There was no change in FTC Cmax or AUC, but Cmin increased by 20%. Tenofovir Cmax, AUC and Cmin were unaltered.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking